Navigation Links
Qualyst Transporter Solutions, LLC Announces Launch of New FDA Services Offering
Date:6/26/2012

RESEARCH TRIANGLE PARK, N.C., June 26, 2012 /PRNewswire-iReach/ -- Qualyst Transporter Solutions, LLC has launched a contract service offering using a clinically-relevant model to assess FDA concerns on drug transporter related hepatic drug-drug interactions.  The newest FDA draft guidance on drug interactions (February, 2012) specifies six hepatic drug transporters of interest, which include three uptake and three efflux transport proteins.

"What is missing in the market is a way to address FDA concerns around transporter-based drug interactions that is predictive of an in vivo outcome." said Dr. Christopher Black, CEO for Qualyst Transporter Solutions.  "Utilizing the gold-standard sandwich-culture hepatocyte model, we have applied our clinically-relevant B-CLEAR® technology in order to produce a cost-effective answer to the FDA's concerns," said Dr. Black.

Many of the ways that current technologies try to address the FDA concerns involve in vitro transfected systems.  Data from these systems are difficult to translate into reliable in vivo knowledge. An integrated in vitro system, like hepatocytes, with multiple localized, functioning, and expressed uptake and efflux transporters, is required to accurately predict and describe in vivo transporter-based drug interactions.

Experiments can be performed in hepatocytes from multiple species, including humans, and the streamlined results are provided as a percent change from control.  Clinically relevant positive controls are included in order to gauge the relative inhibitory potency of the tested compounds.  Qualyst Transporter Solutions has a large historical data base which can help provide clinical perspective on the effects of your compound for an FDA submission.   This can be important since many models overestimate inhibitory interactions or there may be inhibitory effects on a single transporter that can be compensated for by other transporters.  You need an integrated system to evaluate this.  "Because we have hundreds of studies and years of experience with a variety of compound behavior, we can provide perspective to results that is difficult to get anywhere else and critical for the FDA," said Dr. Kenneth Brouwer, CSO.

Qualyst Transporter Solutions only uses Transporter Certified™ hepatocytes and clinically-relevant probe substrates along with positive control inhibitors to examine the potential for in vivo relevant transporter-based drug interactions.  The key to obtaining in vivo-relevant answers is to use a fully integrated, functioning cell system that has been certified.  "We certify our hepatocytes to ensure a fully functioning complement of uptake and efflux transporters, which guarantees that the results are in vivo-relevant," said Dr. Brouwer.

About Qualyst Transporter Solutions, LLC

Qualyst Transporter Solutions commercializes novel and proprietary drug transport and hepatobiliary disposition products for drug discovery and development.  Qualyst Transporter Solutions products provide answers to transporter questions that arise in drug discovery and development.  For additional information, please refer to the company's web site at www.qualyst.com or call (919) 313-6500.

Media Contact: Christopher Black Qualyst Transporter Solutions, LLC, 919-297-8681, chrisblack@qualyst.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

 


'/>"/>
SOURCE Qualyst Transporter Solutions, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Chandler Chicco Companies Acquires Haas & Health Partner Public Relations and SanCom Creative Communication Solutions, Creating Unrivalled Healthcare Communication Capability in Germany
2. Amarillo Biosciences Announces Plan to Open Asia Operations Center in Taipei, Taiwan
3. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of American Oriental Bioengineering Inc.
4. Pacific BioStorage Announces an Exciting New First for The Life Sciences Industry in Southern California
5. JH Technologies Announces Launch of Their New Website
6. Cetero Research Announces Executive Appointments and New Company Name
7. American Botanical Council Announces New Publication "Herbal News & Events"
8. SEE ALGAE Technology GmbH Announces Sale of Algae Farm to Brazils Grupo JB
9. 5AM Solutions Announces Release of the Ion AmpliSeq™ Designer v1.2
10. Kitware Announces Opening of Santa Fe Office
11. Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... 2017 , ... The first human cell line HeLa, established in 1951, has ... cross-contamination of human cell lines with HeLa cells were published. Until recently, cross-contamination and ... and is associated with dramatic consequences for research. , In this educational webinar, ...
(Date:6/22/2017)... MA (PRWEB) , ... June 22, 2017 , ... Charm ... ILVO validation. The AMPH test was determined to be appropriate as a screening test ... visual interpretation, on the Charm EZ system, and the Charm EZ Lite system. These ...
(Date:6/20/2017)... Florida (PRWEB) , ... June 20, 2017 , ... Biologist ... in men. While researching her latest book, Men Chase, Women Choose: The Neuroscience of ... that love has a physiological effect on men. ”The logical next step, in my ...
(Date:6/20/2017)... June 20, 2017  Kibow Biotech Inc., a pioneer ... the issuance of a new patent covering a unique ... the U.S. Patent and Trademark Office on May 23 ... the Buzz of Bio award in 2014 in ... developing non-drug approaches to chronic disease. Renadyl™, the first ...
Breaking Biology Technology:
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
(Date:3/30/2017)... 30, 2017  On April 6-7, 2017, Sequencing.com will ... hackathon at Microsoft,s headquarters in ... focus on developing health and wellness apps that provide ... the Genome is the first hackathon for personal ... largest companies in the genomics, tech and health industries ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
Breaking Biology News(10 mins):